Xeris Adds Ex-Viatris Executive to Board
Specialty pharma companies are adding international commercial and audit experience to their boards as portfolios grow across markets.
Updated on Nov. 2, 2026 in People
Xeris Biopharma has appointed Menassie M. Taddese to its Board of Directors, effective November 2, 2026, and he will also serve on the Board's Audit Committee. The appointment, announced via Business Wire, brings a former Viatris and Pfizer executive into the boardroom of a company selling three commercial products.
Why it matters
Taddese brings more than 20 years of Pfizer experience and recent leadership of a roughly $3 billion Viatris business spanning more than 125 markets, which signals Xeris is adding international commercial operating depth. For operators, board appointments of this kind often reflect how a company plans to scale sales, compliance and cross-market execution as its portfolio grows.
The appointment adds a director with a roughly $3 billion, 125-market Viatris business and a Pfizer tenure of more than 20 years to a company with three commercially available products. Taddese's background spans nearly 30 years of global leadership experience, per the announcement.
The players
Xeris Biopharma
A specialty pharmaceutical company that markets Recorlev, Gvoke and Keveyis and is developing the once-weekly hypothyroidism injection XP-8121.
Menassie M. Taddese
A pharmaceutical executive with more than 20 years at Pfizer and recent leadership of Viatris's emerging markets business, now an independent director and Audit Committee member at Xeris and Medexus Pharmaceuticals.
Viatris
A global pharmaceutical company formed to combine branded and generic medicines, where Taddese most recently led an emerging markets business of roughly $3 billion across more than 125 markets.
Medexus Pharmaceuticals
A Canadian-listed specialty pharmaceutical company (TSX: MDP) on whose board Taddese serves as an independent director and Audit Committee chair.
The details
Taddese most recently served as President, Emerging Markets at Viatris, where he led an approximately $3 billion operation covering more than 125 markets and about 3,500 employees. Earlier, he spent more than 20 years at Pfizer. He also serves as an independent director and Chair of the Audit Committee at Medexus Pharmaceuticals (TSX: MDP), and his Audit Committee role at Xeris places him on a committee that typically oversees financial reporting and internal controls. Xeris's commercial lineup includes Recorlev, Gvoke and Keveyis, and its pipeline is led by XP-8121, a once-weekly subcutaneous injection for hypothyroidism described as Phase 3-ready.
Timeline
November 2, 2026: Taddese's Xeris Board appointment takes effect, the same day the announcement was made.
Market Landscape
Taddese's move follows his career path from more than 20 years at Pfizer to leading emerging markets at Viatris, a pattern in which senior global pharma executives increasingly join boards of mid-sized specialty companies. The Audit Committee seat signals that Xeris is recruiting finance-literate directors as it manages a growing commercial portfolio.
Operators in specialty pharma should note that boards are adding international commercial and audit expertise as portfolios expand across markets. Companies evaluating governance and audit committee structure may find it useful to review director qualifications with qualified counsel or accountants.
The takeaway
Boards that add audit-committee members with multi-market commercial experience are signaling a focus on scaling operations beyond a single product base. Operators tracking governance changes at specialty pharma peers should watch whether similar appointments follow as pipeline assets advance toward market.
Further reading
For more on how leadership moves shape pharmaceutical operations, explore our People coverage.
Source note: This article includes information reported by Firstwordpharma.
